Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of alpha amino acid amides. It is an experimental drug and functions as a covalent inhibitor of cathepsin S—a cysteine protease involved in antigen presentation and immune system regulation. The molecule contains a nitrile warhead that forms a covalent bond with the active site cysteine residue of cathepsin S. Its primary use has been in structural biology studies to understand enzyme inhibition mechanisms and for drug design targeting papain-like cysteine proteases such as cathepsin S[5][7]. There are no known approved therapeutic indications or marketed formulations for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(1-cyanocyclopropyl)-3-({[(2S)-5-oxopyrrolidin-2-yl]methyl}sulfonyl)-N~2~-[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]-L-alaninamide.